Martek: A Brainteaser for Investors
Slide Show >>
Docosahexaenoic acid is a formidable-looking term, but under its friendlier acronym, DHA, Martek Biosciences (MATK) sells the omega-3 fatty acid to infant-formula producers. But it seems the domestic industry leader in DHA needs to nurse itself back to health. The stock excelled in the second half of 2002 and during 2003, eventually topping $70 per share, but later, it stumbled badly. Early this September, it hit a multiyear low of $20.57—and it might still be overvalued.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.
- This $14 Million Atlanta Home With Bunker Is ‘Safest in America’
- Separatists Pledge to Fight On After Spain Moves to Oust Catalan Leaders
- These Cities Make NYC Housing Look Dirt Cheap
- GE's New CEO Vows Sweeping Change After ‘Unacceptable’ Report
- Greenwich Mansion Listings Pulled to Wait for a Better Day